Imaging the folate receptor on cancer cells with 99mTc- etarfolatide: Properties, clinical use, and future potential of folate receptor imaging

Alan H. Maurer; Philip Elsinga; Stefano Fanti; Binh Nguyen; Wim J.G. Oyen; Wolfgang A. Weber

doi:10.2967/jnumed.113.133074

Imaging the folate receptor on cancer cells with ^99mTc- etarfolatide: Properties, clinical use, and future potential of folate receptor imaging

Alan H. Maurer, Philip Elsinga, Stefano Fanti, Binh Nguyen, Wim J.G. Oyen, Wolfgang A. Weber

Research output: Contribution to journal › Review article › peer-review

55 Scopus citations

Abstract

Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non- small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. ^99mTc-etarfolatide, a ^99mTc-labeled folate conjugate, is in latephase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FRimaging agent and how it may be used to direct FR-targeted therapy.

Original language	English
Pages (from-to)	701-704
Number of pages	4
Journal	Journal of Nuclear Medicine
Volume	55
Issue number	5
DOIs	https://doi.org/10.2967/jnumed.113.133074
State	Published - 1 May 2014
Externally published	Yes

Keywords

Folate receptor
Imaging
SPECT
SPECT/CT

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2967/jnumed.113.133074

Cite this

@article{9a788a906b114ed582d2ddc04e0ba965,

title = "Imaging the folate receptor on cancer cells with 99mTc- etarfolatide: Properties, clinical use, and future potential of folate receptor imaging",

abstract = "Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non- small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. 99mTc-etarfolatide, a 99mTc-labeled folate conjugate, is in latephase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FRimaging agent and how it may be used to direct FR-targeted therapy.",

keywords = "Folate receptor, Imaging, SPECT, SPECT/CT",

author = "Maurer, {Alan H.} and Philip Elsinga and Stefano Fanti and Binh Nguyen and Oyen, {Wim J.G.} and Weber, {Wolfgang A.}",

year = "2014",

month = may,

day = "1",

doi = "10.2967/jnumed.113.133074",

language = "English",

volume = "55",

pages = "701--704",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "5",

}

TY - JOUR

T1 - Imaging the folate receptor on cancer cells with 99mTc- etarfolatide

T2 - Properties, clinical use, and future potential of folate receptor imaging

AU - Maurer, Alan H.

AU - Elsinga, Philip

AU - Fanti, Stefano

AU - Nguyen, Binh

AU - Oyen, Wim J.G.

AU - Weber, Wolfgang A.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non- small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. 99mTc-etarfolatide, a 99mTc-labeled folate conjugate, is in latephase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FRimaging agent and how it may be used to direct FR-targeted therapy.

AB - Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non- small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. 99mTc-etarfolatide, a 99mTc-labeled folate conjugate, is in latephase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FRimaging agent and how it may be used to direct FR-targeted therapy.

KW - Folate receptor

KW - Imaging

KW - SPECT

KW - SPECT/CT

UR - http://www.scopus.com/inward/record.url?scp=84901327650&partnerID=8YFLogxK

U2 - 10.2967/jnumed.113.133074

DO - 10.2967/jnumed.113.133074

M3 - Review article

C2 - 24732155

AN - SCOPUS:84901327650

SN - 0161-5505

VL - 55

SP - 701

EP - 704

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 5

ER -